microorgan
found
abundantli
associ
mammalian
host
fact
number
microbi
cell
around
time
host
cell
gibson
roberfroid
consist
around
time
microbi
gene
human
microbiom
project
wwwhttp
hmpdaccorg
concept
microbiom
first
suggest
joshua
lederberg
coin
term
microbiom
signifi
ecolog
commun
commens
symbiot
pathogen
microorgan
liter
share
bodi
space
lederberg
mccray
gener
accept
term
microbiota
past
also
refer
microflora
use
describ
bacteri
commun
mucos
surfac
without
lumin
microorgan
bodi
site
eg
skin
overlap
distinct
term
microbiom
nowaday
use
refer
entir
genet
mass
genom
microorgan
mostli
incorrectli
use
describ
bacteri
genom
commun
one
probabl
refer
specif
bacteriom
virom
mansfield
mycobiom
foster
et
al
respect
use
term
microbiom
global
microorgan
combin
ten
oever
netea
microorgan
includ
eucaryot
archaea
bacteria
virus
fungi
live
close
contact
usual
harm
host
consid
benefici
case
exampl
intestin
microbiota
suppli
fatti
acid
scfa
nutrient
colonocyt
cum
et
al
cum
macfarlan
recent
year
research
focus
characteris
microbiota
differ
bodi
site
peopl
lead
human
microbiom
project
nih
hmp
work
group
consider
progress
also
made
defin
understand
microbi
commun
small
anim
especi
avail
genom
sequenc
techniqu
natur
detect
differ
microbiota
characterist
microbiom
composit
healthi
diseas
subject
led
conclus
modifi
microbi
commun
might
benefici
effect
host
health
certain
circumst
applic
probiot
combin
call
synbiot
focu
much
attent
especi
human
canin
intestin
diseas
like
inflammatori
bowel
diseas
ibd
sauter
et
al
ghouri
et
al
rossi
et
al
schmitz
et
al
et
al
probiot
usual
defin
drug
undergo
process
prove
efficaci
applic
diseas
even
target
speci
henc
mani
medic
claim
made
regard
benefici
effect
human
anim
review
focus
known
definit
mechan
action
efficaci
probiot
differ
gi
diseas
dog
summaris
find
reader
make
better
judgement
use
probiot
small
anim
gastroenterolog
recent
dna
sequenc
techniqu
improv
microbi
identif
small
anim
mostli
techniqu
appli
describ
phylogenet
structur
function
capac
gi
microbiom
handl
et
al
swanson
et
al
hooda
et
al
studi
includ
mucos
sampl
intestin
content
differ
segment
gi
tract
suchodolski
et
al
suchodolski
et
al
focus
analysi
faecal
sampl
easier
obtain
et
al
handl
et
al
swanson
et
al
suchodolski
et
al
honneff
et
al
minamoto
et
al
import
compar
studi
bacteri
popul
shown
differ
differ
substrat
intestin
site
momozawa
et
al
gener
bacteri
number
divers
increas
gradual
along
gi
tract
suchodolski
et
al
fig
healthi
canin
stomach
total
bacteri
load
compar
low
rrna
copi
number
mostli
belong
proteobacteria
obtain
gene
sequenc
firmicut
et
al
predomin
speci
helicobact
lactobacillu
spp
healthi
canin
duoden
microbi
commun
report
one
studi
consist
six
primari
phyla
firmicut
obtain
rrna
gene
sequenc
proteobacteria
bacteroidet
spirochaet
fusobacteria
actinobacteria
xenouli
et
al
anoth
studi
evalu
microbiota
jejunum
healthi
dog
identifi
proteobacteria
abund
follow
firmicut
actinobacteria
spirochaet
bacteroidet
fusobacteria
suchodolski
et
al
fig
duoden
jejun
ingesta
sampl
contain
lactobacillal
respect
xenouli
et
al
suchodolski
et
al
also
identifi
four
addit
phyla
jejunum
report
dog
previous
tenericut
cyanobacteria
verrucomicrobia
chloroflex
present
low
frequenc
suchodolski
et
al
ileal
ingesta
healthi
research
dog
predominantli
contain
fusobacteria
firmicut
bacteroidet
suchodolski
et
al
significantli
differ
composit
duoden
jejun
microbiom
composit
especi
order
fusobacterial
clostridial
clostridium
cluster
xi
xiva
predomin
healthi
ileum
also
contrast
duoden
jejun
sampl
ileal
content
much
lower
proport
lactobacillu
spp
whether
variat
true
qualit
quantit
differ
hard
assess
especi
differ
studi
like
due
variat
differ
dna
extract
method
differ
amplif
primer
sequenc
platform
use
eg
vs
rrna
clone
librari
colon
sampl
show
phyla
fusobacteria
bacteroidet
firmicut
around
healthi
dog
suchodolski
et
al
presenc
fusobacteria
cfuml
intestin
content
also
demonstr
use
techniqu
davi
et
al
next
abund
order
present
clostridial
clostridum
cluster
xiva
predomin
member
suchodolski
et
al
cluster
includ
eubacterium
roseburia
ruminococcu
spp
dietari
fibr
ferment
proteobacteria
includ
e
organ
present
low
proport
wherea
lactobacillal
present
level
similar
jejunum
suchodolski
et
al
result
analys
canin
faecal
microbiom
indic
predomin
phyla
fusobacteria
bacteroidet
firmicut
proteobacteria
actinobacteria
xenouli
et
al
suchodolski
et
al
middelbo
et
al
handl
et
al
swanson
et
al
et
al
fig
even
though
studi
provid
evid
administr
prebioticsfibr
diet
abil
manipul
gi
microbiota
dog
spear
et
al
beloshapka
et
al
panasevich
et
al
limit
firstli
tradit
plate
techniqu
qpcr
quantifi
limit
number
bacteria
eg
lactobacillu
sp
bifidobacterium
sp
clostridia
e
coli
mostli
use
spear
et
al
et
al
second
studi
perform
healthi
dog
make
infer
result
diseas
dog
anim
suscept
gi
disturb
eg
weanl
geriatr
difficult
third
faecal
sampl
analys
rather
mucos
biopsi
ingesta
spear
et
al
verlinden
et
al
hang
et
al
et
al
lastli
wide
rang
prebiot
product
dosag
administ
make
comparison
studi
difficult
author
review
recent
analys
faecal
microbiom
dog
chronic
enteropathi
ce
week
dietari
intervent
compar
faecal
microbiom
healthi
dog
switch
diet
use
diseas
dog
hydrolys
protein
diet
could
detect
signific
effect
microbi
composit
divers
attribut
dietari
chang
schmitz
et
al
unpublish
data
research
use
molecular
sequenc
techniqu
clearli
need
examin
effect
dietari
intervent
healthi
dog
dog
gi
diseas
invas
andor
colonis
gi
tract
specif
pathogen
may
profoundli
disturb
integr
intestin
epitheli
barrier
viswanathan
et
al
sever
potenti
gi
pathogen
recognis
dog
includ
clostridium
perfringen
salmonella
spp
e
coli
mark
et
al
howev
also
recognis
commens
isol
similar
frequenc
dog
without
sign
gi
diseas
mark
kather
unter
et
al
busch
et
al
therefor
caus
effect
relationship
organ
gi
diseas
need
interpret
caution
alter
gi
microbiota
regard
pivot
factor
develop
acut
chronic
gi
diseas
sever
studi
attempt
characteris
faecal
microbi
composit
diarrhoeic
dog
acut
diarrhoea
chang
observ
cultur
sequenc
techniqu
includ
increas
abund
clostridium
spp
especi
c
perfringen
e
coli
lactobacillu
enterococcu
spp
concurr
reduct
bacteri
group
make
major
normal
colon
microbiota
faecalibacterium
ruminococcacea
blautia
spp
bell
et
al
minamoto
et
al
guard
et
al
chronic
diarrhoea
significantli
higher
count
bacteroid
sp
found
use
fluoresc
situ
hybridis
analysi
jia
et
al
studi
evalu
larg
group
dog
chronic
diarrhoea
use
qpcr
assay
diseas
dog
significantli
decreas
abund
fusobacteria
ruminococcacea
blautia
spp
faecalibacterium
spp
significantli
increas
abund
bifidobacterium
spp
lactobacillu
spp
e
coli
compar
healthi
dog
minamoto
et
al
sampl
dog
ibd
microbiom
chang
similar
one
observ
peopl
ibd
detect
significantli
reduc
speci
rich
higher
proport
enterobacteriacea
observ
duoden
brush
sampl
dog
ibd
compar
healthi
dog
xenouli
et
al
addit
duoden
mucos
biopsi
higher
abund
proteobacteria
lower
amount
clostridia
found
ibd
compar
healthi
dog
suchodolski
et
al
fig
analysi
faecal
sampl
dog
ibd
reveal
dysbiosi
significantli
lower
bacteri
divers
increas
gammaproteobacteria
ie
e
coli
decreas
erysipelotrichia
clostridia
bacteroidia
minamoto
et
al
b
whether
chang
partial
caus
result
aberr
immun
reaction
seen
gi
tract
ibd
remain
matter
debat
peopl
dog
howev
suspect
bacteri
chang
associ
alter
metabol
function
microbiota
eg
decreas
scfa
concentr
alter
amino
acid
metabol
chang
redox
equilibrium
alter
bile
acid
metabol
therefor
potenti
exacerb
inflammatori
state
host
hall
minamoto
et
al
guard
et
al
probiot
frequent
defin
live
microorgan
consum
adequ
amount
confer
health
benefit
host
faowho
howev
lot
circumst
health
benefit
strictli
proven
given
diseas
applic
host
organ
term
probiot
still
use
would
appropri
describ
probiot
small
anim
live
microorgan
given
intent
improv
host
health
includ
exogen
indigen
bacteri
speci
interact
variou
cellular
compon
within
host
see
prebiot
defin
select
ferment
ingredi
result
specif
chang
composit
andor
activ
gastrointestin
microbiota
thu
also
benefit
host
organ
gibson
et
al
roberfroid
et
al
usual
prebiot
fibr
compound
differ
length
pass
undigest
gastrointestin
tract
includ
disaccharid
lactulos
tagatos
polysaccharid
fo
mannan
oligosaccharid
mo
xylooligosaccharid
polydextros
galacto
oligosaccharid
prebiot
like
inulin
hugh
rowland
et
al
roberfroid
et
al
koh
et
al
final
synbiot
prepar
combin
probiot
prebiot
concept
first
introduc
mixtur
probiot
prebiot
benefici
affect
host
improv
surviv
implant
live
microbi
dietari
supplement
gastrointestin
tract
select
stimul
growth
andor
activ
metabol
one
limit
number
bacteria
thu
improv
host
welfar
gibson
roberfroid
food
agricultur
organ
unit
nation
fao
recommend
term
synbiot
use
net
health
benefit
observ
synergist
probiot
enhanc
mucos
health
sever
propos
mechan
includ
displac
intestin
pathogen
lee
et
al
product
antimicrobi
substanc
jone
versalov
enhanc
immun
respons
pagnini
et
al
andor
variou
metabolit
soo
et
al
probiot
compet
potenti
pathogen
interf
adher
intestin
mucosa
induct
mucusmucin
product
collado
et
al
mechan
thought
strain
specif
strain
increas
adher
capabl
eg
l
rhamnosu
gg
lgg
strain
abl
increas
adher
pathogen
intestin
mucu
collado
et
al
addit
probiot
bacteria
produc
variou
antimicrobi
substanc
exampl
fatti
acid
lactic
acid
acet
acid
saarela
et
al
lactobacillu
spp
decreas
toxin
gene
express
product
salmonella
ecoli
c
perfringen
vitro
et
al
allaart
et
al
bayoumi
griffith
inactiv
toxin
product
proteas
ex
vivo
castagliuolo
et
al
immun
modul
host
organ
especi
intestin
epitheli
cell
iec
might
occur
microbi
cell
wall
compon
metabolit
dna
oelschlaeg
thoma
versalov
effect
mostli
shown
vitro
also
anim
model
inflamm
includ
mainten
fortif
tight
junction
prolong
surviv
iec
induct
iga
product
oelschlaeg
thoma
versalov
intact
viabl
bacteria
may
essenti
probiot
effect
effect
could
mediat
cell
wall
compon
structur
divers
secret
molecul
eg
peptid
lipopeptid
lipopolysaccharid
lp
dna
rna
et
al
sever
mechanist
studi
show
key
biolog
signal
pathway
like
nuclear
factor
kappa
b
protein
map
kinas
aktphosphatidyl
kinas
peroxisom
prolifer
activ
transcript
receptor
gamma
target
probiot
product
vitro
vivo
thoma
versalov
fig
pathway
modifi
differ
way
individu
probiot
strain
clearli
effect
even
bacteri
strain
speci
alter
cellular
respons
differenti
exampl
lactobacillu
reuteri
atcc
pta
inhibit
factor
alpha
product
myeloid
cell
vitro
suppress
activ
pathway
wherea
anoth
l
reuteri
strain
dsm
inhibit
product
lin
et
al
detail
cellular
interact
specif
probiot
strain
summaris
sever
review
oelschlaeg
thoma
versalov
fijan
vitetta
et
al
figur
effect
probiot
intestin
overal
health
mostli
studi
human
rodent
model
human
diseas
culligan
et
al
much
limit
data
avail
veterinari
speci
callaway
et
al
although
probiot
prebiot
administ
dog
increas
frequenc
investig
evalu
complex
interplay
probiot
small
anim
host
cell
immun
function
effect
intestin
microbi
composit
et
al
vivo
studi
dog
rather
crude
ex
vivo
experi
sauter
et
al
schmitz
et
al
addit
investig
specif
companion
anim
studi
effect
select
probiot
strain
probiot
mixtur
microbiom
target
effect
exampl
cytokin
sauter
et
al
schmitz
et
al
date
four
bacteri
strainsproduct
examin
european
food
safeti
author
efsa
safeti
efficaci
probiot
feed
addit
dog
includ
two
enterococcu
faecium
strain
e
faecium
ncimb
e
faecium
ncimb
lactobacillu
acidophilu
dsm
bifidobacterium
sp
animali
product
contain
e
faecium
strain
alreadi
approv
use
farm
anim
time
approv
small
anim
sought
one
strain
efsa
conclus
enough
inform
provid
consid
safe
use
dog
human
contact
treat
dog
e
faecium
ncimb
e
faecium
strain
ncimb
consid
unlik
repres
hazard
target
speci
even
suppli
overdos
shown
favour
growth
shed
haemolyt
ecoli
dog
cat
product
contain
lactobacillu
acidophilu
dsm
efsa
establish
safeti
concern
strain
sensit
medic
relev
antibiot
except
ciprofloxacin
data
effect
probiot
shed
intestin
pathogen
dog
provid
consid
potenti
respiratori
sensitis
data
request
efsa
reach
final
conclus
latest
probiot
strain
assess
bifidobacterium
animali
strain
strain
design
detail
avail
requir
regard
assess
antibiot
resist
met
strain
resist
clindamycin
genet
basi
resist
could
establish
base
two
studi
provid
effect
b
animali
paramet
dog
consid
question
biolog
relev
efsa
could
conclud
efficaci
product
apart
strain
mention
probiot
synbiot
avail
nutrit
supplement
dog
europ
usa
even
though
product
avail
europ
date
contain
e
faecium
strain
ncimb
sometim
combin
bacteri
strain
differ
prebiot
product
mostli
specif
approv
test
hand
e
faecium
ncimb
use
wide
experiment
set
assess
effect
immun
function
gut
health
see
bacteri
strain
avail
supplement
dog
contain
differ
strain
lactobacilli
l
acidophilu
l
casei
l
plantarum
l
paracasei
l
lacti
l
rhamnosu
l
salivariu
bifidobacteria
b
infanti
b
lacti
b
longum
b
bifidum
bacillu
subtili
coagulan
case
yeast
saccharomyc
cerevisia
fungi
aspergillu
oryza
howev
limit
data
avail
safeti
efficaci
microorganismsproduct
health
claim
associ
microorgan
e
faecium
test
probiot
experiment
set
dog
exampl
saccharomyc
boulardii
investig
small
pilot
studi
present
congress
abstract
dog
ibd
enteropathi
bresciani
et
al
significantli
improv
clinic
activ
score
serum
albumin
level
compar
control
dog
bresciani
et
al
apart
singl
bacteri
strain
test
vitro
detail
probiot
product
also
test
certain
degre
clinic
set
dog
studi
limit
use
e
faecium
swanson
et
al
sauter
et
al
et
al
schmitz
et
al
sever
probiot
cocktail
use
variabl
effect
exampl
mixtur
lactobacilli
show
promis
ex
vivo
result
regard
creat
toler
microenviron
gut
significantli
improv
outcom
administ
clinic
trial
sauter
et
al
anoth
studi
strain
product
approv
use
peopl
vsl
administ
dog
ibd
lead
clinic
immunolog
improv
rossi
et
al
includ
four
lactobacilli
l
acidophilu
l
plantarum
l
paracasei
l
delbrueckii
ssp
bulgaricu
three
bifidobacteria
b
breve
b
longum
b
infanti
streptococcu
thermophilu
sever
bacteri
strain
mostli
lactic
acid
produc
bacteria
lab
isol
canin
faec
origin
use
speci
peopl
test
probiot
potenti
vitro
current
avail
commerci
product
studi
especi
focus
surviv
properti
strain
low
ph
mimic
passag
stomach
resist
degrad
bile
acid
small
intestin
adhes
properti
intestin
mucu
potenti
either
produc
antimicrobi
peptid
inhibit
vitro
growth
pathogen
mostli
e
coli
salmonella
ssp
function
genet
properti
eg
ferment
carbohydr
effect
also
assess
studi
main
outcom
summaris
tabl
littl
known
appropri
dose
probiot
gener
small
anim
let
alon
specif
diseas
surviv
characterist
probiot
strain
especi
e
faecium
test
vitro
vivo
low
environment
ph
mimick
gastric
passag
presenc
bile
adhes
mucu
recoveri
live
bacteria
faec
dog
oral
administr
et
al
et
al
et
al
overal
entir
clear
probiot
surviv
even
necessari
benefici
effect
exampl
dna
suffici
kant
et
al
evid
even
probiot
bacteria
caus
immun
modul
host
zhong
et
al
also
littl
inform
regard
possibl
interact
strain
formul
even
though
studi
experiment
rodent
human
show
synergist
effect
measur
outcom
baillon
et
al
effect
formul
liquid
capsul
natur
sourc
potenti
probiot
yoghurt
raw
green
tripe
ferment
plant
materi
mostli
unexplor
date
preliminari
data
effect
feed
raw
meat
prebiot
fibr
yeast
cell
wall
extract
composit
faecal
microbiota
avail
beloshapka
et
al
chang
depend
meat
protein
sourc
chicken
vs
beef
less
evid
minor
chang
faecal
microbiota
composit
seen
prebiot
ad
eg
greater
presenc
fusobacteria
lower
abund
faecalibacterium
signific
observ
chang
howev
remain
unclear
especi
studi
perform
healthi
dog
furthermor
studi
evalu
faecal
sampl
notic
minor
chang
howev
recent
studi
suggest
probiot
mixtur
ie
vsl
abl
induc
major
chang
ileal
microbiota
colit
mice
also
dog
chronic
enteropathi
mar
et
al
white
et
al
qualiti
control
also
issu
probiot
product
usual
classifi
nutrit
supplement
qualiti
control
drug
legal
requir
larg
amount
data
avail
qualiti
etc
commerci
avail
probiot
one
studi
assess
microbi
compon
dog
food
claim
contain
probiot
wees
arroyo
none
commerci
diet
contain
claim
organ
wherea
one
list
compon
could
isol
around
sampl
eleven
sampl
contain
addit
relat
organ
test
diet
show
relev
bacteri
growth
author
knowledg
publish
studi
far
assess
whether
claim
bacteri
qualiti
quantiti
probiot
nutrit
supplement
accord
label
claim
interestingli
even
though
e
faecium
wide
use
probiot
strain
small
anim
mani
studi
focus
safeti
effect
administ
healthi
dog
studi
perform
nestl
purina
product
technolog
centr
puppi
differ
popular
dog
breed
assign
one
two
differ
diet
wean
benyacoub
et
al
one
diet
commerci
complet
dog
food
supplement
control
group
diet
stabl
encapsul
form
e
faecium
dosag
cfu
ad
treatment
group
main
outcom
measur
includ
determin
total
faecal
iga
total
immunoglobulin
gamma
igg
iga
serum
concentr
quantif
circul
lymphocyt
subset
flow
cytometri
food
intak
weight
routin
laboratori
paramet
complet
blood
count
serum
biochemistri
also
evalu
end
studi
period
year
puppi
consum
test
diet
significantli
higher
total
faecal
serum
iga
level
serum
igg
compar
control
group
addit
iga
igg
canin
distemp
viru
also
significantli
higher
e
puppi
compar
control
week
paramet
differ
group
studi
conclud
e
faecium
enhanc
specif
immun
function
young
dog
benyacoub
et
al
clinic
relev
question
measur
endpoint
necessarili
correl
healthier
intestin
overal
evid
justifi
use
e
faecium
condit
limit
second
studi
investig
effect
e
faecium
healthi
dog
strain
use
e
faecium
isol
enumer
commerci
avail
canin
food
et
al
oral
administ
healthi
adult
dog
differ
breed
age
week
daili
dosag
cfu
faecal
cultur
blood
sampl
routin
biochemistri
valu
obtain
end
treatment
period
well
month
cessat
probiot
administr
e
faecium
treatment
caus
clinic
strain
persist
faec
month
cessat
treatment
reach
averag
concentr
log
cfu
total
concentr
lab
increas
bacteria
staphylococcu
spp
decreas
faecal
sampl
abund
e
coli
influenc
total
serum
lipid
protein
decreas
dog
treatment
cholesterol
within
refer
rang
dog
end
treatment
period
studi
therefor
infer
benefici
influenc
e
faecium
canin
health
possibl
even
obes
even
though
obes
anim
examin
studi
benefici
effect
normalis
cholesterol
question
et
al
addit
studi
shown
persist
oral
administ
probiot
dog
lack
control
group
entir
clear
strain
identif
perform
henc
result
studi
interpret
caution
also
studi
question
definit
probiot
fulfil
use
e
faecium
relev
benefit
increas
faecal
iga
elev
titr
lower
cholesterol
demonstr
number
studi
investig
safeti
effect
n
lab
prepar
healthi
dog
exampl
effect
measur
outcom
administr
l
acidophilu
controversi
one
studi
administr
l
acidophilu
adult
dog
associ
chang
haematolog
immunolog
paramet
increas
red
blood
cell
rbc
hct
haemoglobin
neutrophil
monocyt
serum
igg
reduc
rbc
fragil
serum
concentr
question
clinic
relev
baillon
et
al
anoth
studi
supposedli
benefici
chang
observ
composit
microbiota
faecal
metabolit
attribut
addit
prebiot
fo
l
acidophilu
ncfm
swanson
et
al
l
fermentum
test
group
two
studi
et
al
lab
l
fermentum
origin
isol
faec
healthi
dog
tibetan
terrier
shown
good
vitro
surviv
ph
h
presenc
bile
well
good
adhes
properti
canin
human
intestin
mucu
unaccept
antimicrobi
resist
et
al
oral
administ
healthi
dog
variou
breed
dose
cfu
day
signific
increas
faecal
lactobacilli
enterococci
serum
total
protein
total
lipid
reduct
blood
glucos
note
studi
strain
administ
form
healthi
dog
shown
persist
gi
tract
increas
scfa
concentr
addit
reduct
clostridia
bacteria
coliform
aeromona
pseudomona
also
note
faecal
cultur
et
al
studi
impli
desir
outcom
howev
approach
member
clostridia
identifi
part
normal
benefici
gut
flora
see
deduct
regard
gut
health
difficult
make
data
detail
investig
evalu
whether
probiot
strain
reduc
specif
potenti
pathogen
c
perfringen
rather
clostridia
gener
would
need
lactobacillu
animali
isol
faec
healthi
adult
dog
test
vitro
vivo
nine
dog
given
day
day
cultur
faecal
lactobacilli
concentr
increas
enterococci
reduc
compar
begin
trial
henc
strain
conclud
probiot
properti
biagi
et
al
howev
conclus
nearli
imposs
make
cultur
outcom
assess
control
group
recent
studi
use
genet
engin
strain
lactobacillu
casei
strain
design
avail
capabl
produc
biolog
activ
canin
granulocyt
macrophag
coloni
stimul
factor
investig
properti
probiot
dog
chung
et
al
administ
cfu
week
treat
dog
show
increas
monocyt
count
serum
iga
canin
igg
compar
dog
fed
regular
diet
without
probiot
supplement
dog
receiv
strain
l
casei
chung
et
al
clinic
relev
find
safeti
efficaci
administr
strain
remain
open
differ
strain
bifidobacterium
animali
kelley
et
al
unspecifi
strain
isol
dog
faec
investig
group
found
caus
undesir
effect
administr
healthi
dog
increas
number
cultur
lab
lower
count
coliform
bacteria
canin
faec
faecal
serum
paramet
well
phagocyt
activ
peripher
blood
leucocyt
especi
neutrophil
improv
treat
dog
compar
untreat
control
group
effect
could
detect
sever
week
treatment
ceas
et
al
relev
remain
unclear
especi
method
use
rather
crude
assess
immun
function
overal
data
improv
gut
health
immunolog
statu
dog
use
lactobacilli
bifidobacteria
compel
especi
light
fact
known
increas
certain
bacteri
phyla
correl
improv
gi
function
lower
incid
diarrhoeic
diseas
bacilli
thought
author
repres
superior
probiot
lab
sporul
thu
resist
environment
stress
low
ph
biourg
et
al
et
al
howev
mere
surviv
might
import
featur
probiot
need
test
benefit
clinic
situat
european
countri
probiot
product
contain
bacilli
avail
nutrit
supplement
human
anim
biourg
et
al
shown
benefici
effect
surviv
mice
infect
klebsiella
pneumonia
breed
perform
number
product
anim
biourg
et
al
bacillu
cip
found
persist
ad
canin
food
expos
dri
experi
also
abl
surviv
canin
gi
tract
howev
seem
persist
disappear
faec
day
cessat
administr
german
et
al
one
studi
found
bacillu
subtili
improv
faecal
textur
odour
dog
due
decreas
content
faecal
ammonia
et
al
clinic
relev
find
justif
call
bacilli
probiot
situat
highli
question
usag
bacilli
probiot
recommend
mixtur
probiot
use
healthi
dog
variabl
composit
addit
outcom
measur
differ
mainli
also
due
avail
differ
techniqu
assess
chang
microbi
commun
one
studi
administ
five
potenti
probiot
lab
strain
l
fermentum
l
salivariu
weissella
confus
l
rhamnosu
l
mucosa
five
perman
fistul
beagl
dog
day
manninen
et
al
denatur
gradient
gel
electrophoresi
dgge
demonstr
lab
modifi
domin
indigen
jejun
lab
microbiota
strain
undetect
day
administr
ceas
effect
transient
anoth
studi
et
al
seven
strain
lab
e
faecium
salivaru
ssp
thermophilu
b
longum
l
acidophilu
l
casei
ssp
rhamnosu
l
plantarum
l
delbrueckii
ssp
bulgaricu
administ
healthi
dog
faecal
microbi
commun
assess
use
dgge
gel
rrna
gene
librari
quantit
pcr
rrna
gene
probiot
speci
detect
dog
product
administr
abund
enterococcu
streptococcu
spp
significantli
increas
howev
pyrosequenc
chang
major
bacteri
phyla
observ
studi
conclud
product
well
toler
caus
clinic
administr
product
result
increas
abund
probiot
genera
suffici
caus
signific
chang
overal
microbiom
structur
et
al
certainli
automat
infer
convey
health
benefit
final
synbiot
consist
e
faecium
bacillu
coagulan
l
acidophilu
sever
prebiot
fo
mo
vitamin
administ
trial
healthi
train
sled
dog
chang
composit
faecal
microbiota
assess
use
quantit
pcr
flx
rdna
amplicon
pyrosequenc
et
al
alter
faecal
microbiom
observ
includ
rise
lactobacillacea
increas
faecal
butyr
concentr
across
dog
faecal
score
also
improv
compar
control
group
week
et
al
whether
find
correl
benefici
host
even
incident
remain
unclear
overal
seem
possibl
depend
probiot
strain
mixtur
use
merit
use
probiot
acut
infecti
canin
gi
diseas
administr
probiot
mixtur
vsl
randomis
manner
puppi
confirm
parvovir
enter
lead
increas
percentag
surviv
dog
probiot
group
vs
group
rapid
improv
clinic
score
leucocytelymphocyt
count
arslan
et
al
anoth
studi
signific
reduct
ancylostoma
egg
shed
dog
treat
mixtur
lab
l
acidophilu
atcc
l
plantarum
atcc
l
delbrueckii
ufv
day
compar
untreat
control
group
et
al
similar
result
could
achiev
treatment
canin
giardiasi
e
faecium
week
treatment
differ
cyst
shed
faecal
antigen
shed
faecal
iga
leucocyt
phagocyt
activ
observ
treat
untreat
dog
simpson
et
al
form
acut
diarrhoea
dog
probiot
administ
includ
eg
kennel
stress
idiopath
diarrhoea
result
variabl
depend
probiot
strain
dog
popul
evalu
use
e
faecium
effect
kennel
diarrhoea
might
partial
due
low
preval
diarrhoea
studi
bybe
et
al
faecal
score
significantli
improv
dog
undergo
kennel
stress
supplement
bifidobacterium
animali
compar
untreat
control
group
kelley
et
al
strain
abl
significantli
reduc
time
resolut
clinic
sign
number
dog
receiv
metronidazol
studi
acut
idiopath
diarrhoea
dose
cfu
kelley
et
al
similar
respons
seen
studi
acut
gastroenter
use
probiot
mixtur
l
acidophilu
pediococcu
acidilactici
b
subtili
b
licheniformi
l
farcimini
herstad
et
al
recoveri
time
significantli
reduc
mean
day
ci
day
compar
untreat
control
mean
day
ci
day
compar
larg
dose
kg
three
time
daili
herstad
et
al
inactiv
bacteri
compound
part
enterovaccin
might
also
use
treat
recurr
episod
diarrhoea
eg
dog
one
commerci
avail
prepar
deactiv
whole
bacteria
lysat
ecoli
bacillu
pumilu
morganella
morganii
alcaligen
faecali
shigella
flexneri
bacillu
subtili
enterococcu
faecali
proteu
vulgari
reduc
number
diarrhoea
episod
sever
five
six
treat
dog
cerquetella
et
al
control
dog
pilot
studi
henc
exact
potenti
inactiv
bacteri
mixtur
need
evalu
clinic
studi
interestingli
administr
saccharomyc
boulardii
dog
experiment
diarrhoea
could
prevent
treat
condit
akta
et
al
similar
peopl
pathogenesi
chronic
inflammatori
condit
gi
tract
dog
eg
ceibd
assum
due
aberr
respons
lumin
adher
intestin
microbiota
sartor
hall
german
ampl
evid
immun
dysregul
even
though
exact
type
inflammatori
respons
pathogenesi
elucid
yet
german
et
al
peter
et
al
jergen
et
al
schmitz
et
al
sever
studi
shown
also
alter
intestin
microbiom
present
canin
ceibd
suchodolski
et
al
b
henc
sever
attempt
influenc
composit
microbiota
dog
allevi
clinic
sign
partial
use
probiot
alreadi
shown
properti
vitro
ex
vivo
studi
sauter
et
al
schmitz
et
al
e
faecium
ncimb
assess
treatment
dog
diseas
frd
found
effect
clinic
activ
score
histolog
score
duoden
colon
gene
express
select
gene
associ
specif
lymphocyt
line
schmitz
et
al
addit
also
effect
e
faecium
treatment
gene
protein
express
inflammasom
compound
schmitz
et
al
promis
result
could
achiev
use
probiot
mixtur
frd
dog
combin
lab
l
acidophilu
l
johnsonii
reduc
duoden
interleukin
il
colon
interferon
gamma
mrna
level
number
faecal
enterobacteriacea
wherea
number
lactobacillu
spp
increas
clinic
improv
note
similar
level
dog
receiv
lab
cocktail
compar
dog
treat
diet
alon
sauter
et
al
addit
probiot
mixtur
vsl
strain
formul
pet
detail
use
dog
idiopath
ibd
compar
treatment
regimen
metronidazol
prednisolon
trial
rossi
et
al
clinic
activ
duoden
histolog
score
lymphocyt
intestin
tissu
decreas
group
howev
cell
marker
regulatori
lymphocyt
treg
increas
significantli
treatment
dog
treat
vsl
strain
also
transform
growth
factor
beta
tgfb
cell
like
treg
increas
group
treatment
greater
magnitud
probiot
treat
dog
effect
probiot
express
tight
junction
protein
occludin
significantli
elev
healthi
control
dog
dog
treat
probiot
compar
ibd
dog
microbiom
analysi
base
quantit
pcr
reveal
reduc
abund
faecalibacterium
turicibact
dog
ibd
start
trial
signific
increas
faecalibacterium
observ
anim
treat
vsl
strain
rossi
et
al
noteworthi
faecalibacterium
prausnitzii
advoc
commens
bacterium
peopl
miquel
et
al
lower
abund
intestin
content
faecal
sampl
human
canin
ibd
patient
suchodolski
et
al
fujimoto
et
al
saccharomyc
boulardii
yeast
administ
dog
cepl
healthi
control
dog
small
pilot
clinic
trial
mention
cfu
bodi
weight
bid
day
bresciani
et
al
dog
ce
ple
addit
receiv
standard
medic
treatment
consist
diet
antibiot
andor
immunosuppress
drug
boulardii
detect
faecal
sampl
healthi
dog
treatment
start
present
day
supplement
reach
highest
level
day
cfu
elimin
day
withdraw
treatment
dog
ce
clinic
score
improv
significantli
dog
ple
serum
albumin
valu
increas
significantli
compar
placebo
treatment
duoden
endoscop
histolog
score
differ
treatment
dog
studi
conclud
boulardii
safe
administ
dog
might
use
adjunct
treatment
ce
ple
bresciani
et
al
howev
small
studi
fulli
publish
yet
await
full
result
research
use
boulardii
potenti
probiot
warrant
administr
even
probiot
product
might
limit
abil
influenc
composit
intestin
microbiom
perman
especi
given
fact
microbiom
consist
hundr
microbi
speci
base
assumpt
complex
chang
need
certain
condit
eg
clostridium
difficil
infect
ibd
attempt
transfer
intestin
microbiota
one
subject
anoth
term
faecal
microbi
transplant
fmt
microbiom
restor
therapi
faecal
bacteriotherapi
human
medicin
fmt
mostli
perform
recurr
c
difficil
infect
two
review
show
safe
effect
human
patient
achiev
full
resolut
clinic
sign
gough
et
al
guo
et
al
limit
clinic
data
avail
evalu
use
fmt
ibd
human
pilot
studi
suggest
respons
rate
fmt
chronic
intestin
inflamm
much
lower
compar
c
difficil
infect
colman
rubin
experi
small
anim
regard
safeti
efficaci
fmt
scarc
anecdot
two
congress
abstract
report
preliminari
find
dog
one
case
report
ongo
studi
publish
dog
eosinophil
ibd
year
durat
moder
clinic
sign
convent
therapi
given
fmt
enema
min
retent
time
faecal
consist
improv
within
h
dog
clinic
well
time
report
month
treatment
rrna
gene
sequenc
faecal
microbiom
reveal
day
fmt
dog
faecal
sampl
cluster
donor
baselin
sampl
speci
rich
increas
compar
valu
wees
abstract
report
use
fmt
dog
refractori
presumpt
clostridium
diarrhoea
murphi
et
al
administ
enema
transplant
per
dog
dog
immedi
resolut
diarrhoea
dog
neg
pcr
panel
c
perfringen
alpha
toxin
mention
c
perfringen
part
normal
intestin
flora
dog
henc
remain
unclear
detect
c
perfringen
realli
caus
diarrhoea
rather
part
intestin
dysbiosi
minamoto
et
al
case
need
still
critic
assess
whether
fmt
address
clostridiosi
even
microbiom
chang
suggest
improv
faecal
dysbiosi
author
unpublish
confer
abstract
conclud
fmt
consid
treatment
option
dog
fail
therapeut
option
wees
murphi
et
al
anecdot
evid
use
increas
veterinari
commun
prospect
studi
larg
cohort
dog
need
properli
address
use
fmt
defin
gi
diseas
dog
microbiota
mucos
surfac
especi
gi
tract
dog
complex
composit
vari
site
site
evid
chang
composit
microbiotamicrobiom
associ
certain
diseas
howev
analysi
canin
gi
faecal
microbiota
composit
function
product
metabolit
immunolog
properti
far
complet
even
though
data
microbiom
accumul
accordingli
overal
knowledg
best
characterist
canin
microbi
commens
probiot
patchi
assumpt
best
properti
deriv
human
studi
bacteri
strain
show
promis
potenti
probiot
especi
lab
howev
effect
commonli
use
strain
e
faecium
still
well
understood
particularli
diseas
dog
challeng
compar
outcom
differ
studi
healthi
diseas
dog
huge
variat
probiot
use
type
microorgan
dosag
applic
form
frequenc
measur
outcom
also
consist
overal
seem
author
e
faecium
tend
suitabl
acut
andor
infecti
form
diarrhoea
evid
produc
rather
reaction
schmitz
et
al
wherea
lactobacilli
bifidobacteria
show
pronounc
function
intriguingli
especi
combin
lab
vsl
use
human
medicin
prevent
relaps
ulcer
coliti
promis
treat
chronic
enteropathi
dog
creat
local
environ
rossi
et
al
interest
note
even
infecti
diseas
like
parvovirosi
parasit
infest
probiot
show
benefici
effect
mechan
behind
well
understood
research
warrant
clear
studi
peopl
experiment
rodent
immunolog
outcom
depend
bacteri
strain
even
subspeci
probabl
manner
wees
anderson
evrard
et
al
et
al
respect
host
immun
respons
human
probiot
classifi
author
depend
major
properti
shida
et
al
care
assess
potenti
probiot
target
speci
diseas
possibl
vitro
vivo
necessari
judg
full
potenti
author
even
propos
test
probiot
vitro
tissu
explant
first
perform
vivo
trial
tsilingiri
et
al
howev
might
alway
possibl
veterinari
medicin
also
consider
bacteria
might
alway
appropri
probiot
know
virtual
noth
regard
fungal
even
viral
composit
normal
intestin
tract
mucos
surfac
dog
foster
et
al
evid
yeast
like
saccharomyc
boulardii
might
valid
altern
probiot
need
detail
investig
furthermor
emerg
field
research
bacteri
metabolit
eg
indol
acet
may
potenti
serv
postbiot
faecal
transplant
interest
option
treat
acut
chronic
diarrhoea
dog
howev
much
need
understood
regard
best
perform
safeti
use
recommend
routin
treatment
summari
work
need
done
understand
complex
interplay
potenti
probiot
host
environ
care
investig
mechan
action
detail
measur
outcom
help
understand
probiot
use
condit
chang
intestin
microbiom
necessari
achiev
clinic
remiss
acut
chronic
condit
manuscript
support
fund
author
declar
conflict
interest
author
contribut
equal
manuscript
